Neurobiological Technologies Inc.'s two kernels of news to pop last week - positive interim data from a partner with Xerecept for brain edema, plus a deal with the Buck Institute For Age Research to develop fibroblast growth factor-2 against Huntington's disease - failed to butter up investors, as the value of the firm stayed "inexplicably low," in the words of analyst Russell McAllister of Merriman Curhan Ford. (BioWorld Financial Watch) Read More